

JOSEPH DAMOND
SENIOR VICE PRESIDENT, INTERNATIONAL AFFAIRS
BIOTECHNOLOGY INDUSTRY ORGANIZATION (BIO)

PUBLIC HEARING ON THE
TRANSATLANTIC TRADE AND INVESTMENT PARTNERSHIP
MAY 29-30, 2013

SUMMARY OF PROPOSED TESTIMONY

- Review the significance of biotechnology innovation for the long-term economic and technological competitiveness of the Transatlantic economy, and for the creation of solutions with respect to health care, agricultural productivity and sustainability, and advancement of green technologies.
- Highlight the unique characteristics (and challenges) of biotechnology R&D, investment, and commercialization, and the ability of well-formulated TTIP provisions to address these challenges in order to incentivize innovation on the part of U.S. and EU biotechnology companies.
- Summarize the views of BIO and its members regarding priority objectives to be pursued by U.S. negotiators during the course of TTIP negotiations, namely:
 - Regulatory Cooperation and Convergence for Bio-Pharmaceuticals: BIO urges USTR to pursue a distinct and targeted set of sectoral outcomes on bio-pharmaceuticals as part of the TTIP negotiations on regulatory cooperation and convergence, building on existing efforts and pilot programs between U.S. and EU regulators of these products.
 - Market Access for Bio-Pharmaceuticals: BIO requests USTR to build on previous provisions in U.S. and EU free trade agreements to ensure procedural fairness, transparency, non-discrimination, and science-based decision making with regard to regulatory determinations on pricing and reimbursement of bio-pharmaceuticals.
 - Intellectual Property Rights: BIO urges USTR to seek TTIP outcomes that will advance the highest possible standards of protection and enforceability for intellectual property rights related to bio-pharmaceutical and agricultural biotechnology innovation, and to seize upon TTIP as an opportunity to promote deeper harmonization of substantive and procedural approaches to patents and protected data.
 - Normalization of Trade in Agricultural Biotechnology Products: BIO regards the TTIP as an opportunity to collaborate in finding constructive solutions to long-standing problems surrounding trade in the products of agricultural

biotechnology, focusing in particular on full and effective implementation of existing EU laws and procedural timelines for approving agricultural biotechnology products.